Manufacturing MSCs for commercial application: an interview with Ross Macdonald.

Manufacturing MSCs for commercial application: an interview with Ross Macdonald.
Regen Med. 2019 Nov 07;:
Authors: Macdonald R
Abstract
Ross Macdonald is the CEO and Managing Director of Cynata Therapeutics Limited (Australia). He has over 30 years of experience and a track record of success in pharmaceuticals and biotechnology businesses. His career history includes positions as Vice President of Business Development for Sinclair Pharmaceuticals Ltd (now Sinclair IS Pharma), a UK-based specialty pharmaceuticals company, and Vice President of Corporate Development for Stiefel Laboratories, Inc., then the largest independent dermatology company in the world and acquired by GlaxoSmithKline in 2009 for £2.25 billion. He has also served as the CEO of Living Cell Technologies Ltd, Vice President of Business Development of Connetics Corporation and Vice President of Research and Development of F H Faulding & Co Ltd.
PMID: 31697200 [PubMed - as supplied by publisher]

Source: Regenerative Medicine - November 6, 2019 Category: Genetics & Stem Cells Authors: Macdonald R Tags: Regen Med Source Type: research